Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and pro...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Mustafa Seyyar, Ali Kalem, Mürsel Sali, Berkan Karabuğa, Taha Koray Sahin, Ahmet Kürşad Dişli, Alper Türkel, Berkan Karadurmuş, Ece Şahin Hafızoğlu, Nilüfer Avcı, Irem Bilgetekin, Naziyet Köse Baytemur, Esma Uguztemur, Utku Oflazoğlu, Hasibe Bilge Gür, İlhan Hacıbekiroğlu, Aysun Fatma Akkuş, Sernaz Topaloğlu, Ayberk Bayramgil, Özgecan Dülgar Kaya, Melike Yazıcı, Teoman Şakalar, Seval Akay, Nargiz Majidova, Murad Guliyev, Özkan Alan, Serkan Gülcü, Tülay Eren, Gökşen İnanç İmamoğlu, Ali Kaan Güren, Osman Köstek, Ahmet Ünlü, Banu Ozturk, Esra Aydın, Shamkhal Safarov, Bekir Doğan, Mehmet Akif Tükenmez, Teyfik Demir, Elif Şahin, Engin Erdemoğlu, Fatma Keskin Uzundere, Osman Bütün, Bülent Karabulut, Mehmet Uzun, Tuba Baydaş, Elanur Karaman, Hacı Arak, Ferhat Ekinci, Musa Barış Aykan, İsmail Ertürk, Deniz Can Guven, Adem Deligönül, Cengiz Karaçin, Öztürk Ateş, Mevlüde İnanç, Havva Yeşil, Sercan Aksoy, Tolga Köşeci, İlker Nihat Ökten, Hasan Çağrı Yıldırım, Devrim Çabuk
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2026-06-01
Serie:	Current Oncology
Ämnen:	BRCA mutation CDK4/6 inhibitors hormone receptor-positive metastatic breast cancer palbociclib real-world study
Länkar:	https://www.mdpi.com/1718-7729/33/6/365
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!